Ivermectin and Gynecologic Cancer: What are the data?

•Ivermectin is currently approved by the US Food and Drug Administration (FDA) in 1996 as an oral medication for intestinal strongyloidiasis and onchocerciasis.•The data on ivermectin as a gynecologic cancer-fighting compound is lacking.•Clinical studies on ivermectin use in cancer are limited to ef...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Gynecologic oncology reports Ročník 60; s. 101803
Hlavní autoři: Mujumdar, Vaidehi, Huang, Marilyn, Smith, Lindsey Chippendale, Musa, Fernanda
Médium: Journal Article
Jazyk:angličtina
Vydáno: Elsevier Inc 01.08.2025
Elsevier
Témata:
Anti-helminthic
COVID-19
Gynecologic cancers
Ivermectin
Wonder drug
COVID-19
Gynecologic cancers
Wonder drug
Anti-helminthic
Ivermectin
ISSN:2352-5789, 2352-5789
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:•Ivermectin is currently approved by the US Food and Drug Administration (FDA) in 1996 as an oral medication for intestinal strongyloidiasis and onchocerciasis.•The data on ivermectin as a gynecologic cancer-fighting compound is lacking.•Clinical studies on ivermectin use in cancer are limited to effects observed in cell lines.•We have not assessed ivermectin’s safety and efficacy in gynecologic cancers.•We do not recommend and strongly caution the use of ivermectin in the treatment of gynecologic cancers.
ISSN:2352-5789
2352-5789
DOI:10.1016/j.gore.2025.101803